Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative BC (HRPBC) was the most common (65.9%), followed by HR-positive and HER2-positive BC (HHPBC) (11.7%), HR-negative and HER2-positive BC (HER2PBC, 10.2%), and HR-negative and HER2-negative BC (TNBC, 12.2%) [2]. Here, ERBB2 is linked to breast cancer.